475 related articles for article (PubMed ID: 31836861)
1. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.
Tambuyzer E; Vandendriessche B; Austin CP; Brooks PJ; Larsson K; Miller Needleman KI; Valentine J; Davies K; Groft SC; Preti R; Oprea TI; Prunotto M
Nat Rev Drug Discov; 2020 Feb; 19(2):93-111. PubMed ID: 31836861
[TBL] [Abstract][Full Text] [Related]
2. Development of orphan drugs for rare diseases.
Yoo HW
Clin Exp Pediatr; 2024 Jul; 67(7):315-327. PubMed ID: 37402468
[TBL] [Abstract][Full Text] [Related]
3. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
Micallef J; Blin O
Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
[TBL] [Abstract][Full Text] [Related]
4. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
5. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Orphan Drug Indications: 2010-2018.
Kimmel L; Conti RM; Volerman A; Chua KP
Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
[TBL] [Abstract][Full Text] [Related]
7. Orphan drug development in China: progress and challenges.
Zhang S; Chen L; Zhang Z; Zhao Y
Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
[No Abstract] [Full Text] [Related]
8. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
Guan X; Zhang J; Man C; Ni B; Shi L
J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
[TBL] [Abstract][Full Text] [Related]
9. Drug Repurposing for Rare Diseases.
Roessler HI; Knoers NVAM; van Haelst MM; van Haaften G
Trends Pharmacol Sci; 2021 Apr; 42(4):255-267. PubMed ID: 33563480
[TBL] [Abstract][Full Text] [Related]
10. Protein replacement therapies for rare diseases: a breeze for regulatory approval?
Gorzelany JA; de Souza MP
Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010
[TBL] [Abstract][Full Text] [Related]
11. Drug repurposing in rare diseases: Myths and reality.
Fetro C; Scherman D
Therapie; 2020 Apr; 75(2):157-160. PubMed ID: 32241561
[TBL] [Abstract][Full Text] [Related]
12. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
13. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
Lutz T; Lampert A; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
[TBL] [Abstract][Full Text] [Related]
14. Innovative design and analysis for rare disease drug development.
Chow SC; Huang Z
J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
[TBL] [Abstract][Full Text] [Related]
15. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
16. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
Harada K; Toriyabe K; Ono S
J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
[TBL] [Abstract][Full Text] [Related]
17. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
18. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
19. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Mechler K; Mountford WK; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
